What is BridgeBio Pharma's stock issuance proceeds?

BridgeBio Pharma (BBIO) reported stock issuance proceeds of $22.59M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing new shares of company stock.

How do you interpret stock issuance proceeds?

Higher proceeds indicate successful capital raising or employee participation in equity plans, though it may signal potential shareholder dilution.

How does stock issuance proceeds compare across companies?

High for growth-stage biotech companies relying on equity markets for R&D funding.

BridgeBio Pharma BBIO Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Ionis PharmaceuticalsIONS

$57.3M+2,457%

Revolution Medicines, Inc.RVMD

$12.21M+1,270%

Roivant SciencesROIV

-$217.17M—

Arrowhead ResearchARWR

$46.83M—

Neurocrine BiosciencesNBIX

$23.6M-26.5%

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's stock issuance proceeds?: BridgeBio Pharma (BBIO) reported stock issuance proceeds of $22.59M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing new shares of company stock.
How do you interpret stock issuance proceeds?: Higher proceeds indicate successful capital raising or employee participation in equity plans, though it may signal potential shareholder dilution.
How does stock issuance proceeds compare across companies?: High for growth-stage biotech companies relying on equity markets for R&D funding.